Sharon L. Gardner MD
Associate Professor, Pediatrics, New York University School of Medicine
Join to view full profile
317 E 34th StNew York, NY 10016
Phone+1 212-263-8400
Dr. Gardner is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1989 - 1992
Tower Health/St. Christopher's Hospital for ChildrenResidency, Pediatrics, 1986 - 1989
Drexel University College of MedicineClass of 1986
Certifications & Licensure
NY State Medical License 1989 - 2025
PA State Medical License 1987 - 2002
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014-2015, 2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014-2015, 2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014-2015, 2017
Clinical Trials
- Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer
- Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
- High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas
Publications & Presentations
PubMed
- 16 citationsSafety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.Yazmin Odia, Carl Koschmann, Nicholas A Vitanza, Peter de Blank, Dolly Aguilera
Neuro-Oncology. 2024-05-03 - 40 citationsONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.Isabel Arrillaga-Romany, Sharon L Gardner, Yazmin Odia, Dolly Aguilera, Joshua E Allen
Journal of Clinical Oncology. 2024-05-01 - 1 citationsFinal report of the phase II NEXT/CNS-GCT-4 trial: GemPOx followed by marrow-ablative chemotherapy for recurrent intracranial germ cell tumors.Margaret Shatara, Megan Blue, Joseph Stanek, Yin A Liu, Daniel M Prevedello
Neuro-Oncology Practice. 2024-04-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
